CD8B and neoplasm: Our results showed that tumour expression of CD8a and CD8b (main markers of CD8+ T cells) and NKp46 (a main marker of natural killer, NK cells) increased significantly in the group of mice receiving RGD4C.TPA.IL15IgK immunotherapy, as compared to the control group treated with non‐targeted TPA.IL15IgK (Fig 7A).